Qi Cao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4856608/publications.pdf

Version: 2024-02-01

74	12,789	101384	74018
papers	citations	36 h-index	75 g-index

77	77	77	17676
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457, 910-914.	13.7	1,944
2	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11606-11611.	3.3	1,482
3	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science, 2008, 322, 1695-1699.	6.0	995
4	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature Biotechnology, 2011, 29, 742-749.	9.4	950
5	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 2007, 448, 595-599.	13.7	743
6	An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell, 2010, 17, 443-454.	7.7	743
7	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	2.3	608
8	The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics, 2013, 45, 1392-1398.	9.4	601
9	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	15.2	436
10	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	7.7	397
11	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	7.7	303
12	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. Cancer Research, 2008, 68, 73-80.	0.4	244
13	PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. Cancer Research, 2014, 74, 1651-1660.	0.4	237
14	The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. Neoplasia, 2014, 16, 900-908.	2.3	216
15	Integrative Genomics Analysis Reveals Silencing of Î²-Adrenergic Signaling by Polycomb in Prostate Cancer. Cancer Cell, 2007, 12, 419-431.	7.7	204
16	Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Reports, 2018, 25, 2808-2820.e4.	2.9	201
17	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell, 2011, 20, 187-199.	7.7	191
18	N6-Methyladenosine Modulates Nonsense-Mediated mRNA Decay in Human Glioblastoma. Cancer Research, 2019, 79, 5785-5798.	0.4	181

#	Article	IF	Citations
19	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10284-10289.	3.3	140
20	Therapeutic Targeting of SPINK1-Positive Prostate Cancer. Science Translational Medicine, 2011, 3, 72ra17.	5.8	140
21	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood, 2011, 117, 6172-6183.	0.6	132
22	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. Molecular Cell, 2013, 49, 80-93.	4.5	130
23	The central role of EED in the orchestration of polycomb group complexes. Nature Communications, 2014, 5, 3127.	5.8	130
24	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery, 2011, 1, 35-43.	7.7	91
25	Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer. Neoplasia, 2008, 10, 1285-IN35.	2.3	89
26	The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. Neoplasia, 2005, 7, 1011-1019.	2.3	86
27	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology, 2009, 27, 1005-1011.	9.4	69
28	BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nature Communications, 2018, 9, 500.	5.8	65
29	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. Neoplasia, 2012, 14, 905-IN8.	2.3	59
30	Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning. Journal of Pineal Research, 2019, 67, e12607.	3.4	57
31	A PRC2-independent function for EZH2 in regulating rRNA 2â€²-O methylation and IRES-dependent translation. Nature Cell Biology, 2021, 23, 341-354.	4.6	54
32	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene, 2020, 39, 6265-6285.	2.6	52
33	Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. International Journal of Cancer, 2019, 145, 415-426.	2.3	51
34	Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. International Journal of Oncology, 2018, 53, 137-147.	1.4	49
35	Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. Frontiers in Pharmacology, 2017, 8, 495.	1.6	48
36	TMPRSS2â€“ERG-Mediated Feed-Forward Regulation of Wild-Type ERG in Human Prostate Cancers. Cancer Research, 2011, 71, 5387-5392.	0.4	42

#	Article	IF	Citations
37	Role of Autophagy in Renal Cancer. Journal of Cancer, 2019, 10, 2501-2509.	1.2	40
38	Long noncoding RNA SNHG12 indicates the prognosis of prostate cancer and accelerates tumorigenesis via sponging miRâ€133b. Journal of Cellular Physiology, 2020, 235, 1235-1246.	2.0	39
39	A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes. Molecular Cell, 2021, 81, 2246-2260.e12.	4.5	35
40	Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 1516-1528.	3.2	34
41	Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma. Experimental Cell Research, 2017, 358, 269-278.	1.2	30
42	Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis. Biomedicine and Pharmacotherapy, 2019, 118, 109264.	2.5	30
43	LXRÎ± promotes cell metastasis by regulating the NLRP3 inflammasome in renal cell carcinoma. Cell Death and Disease, 2019, 10, 159.	2.7	30
44	PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e9-343.e19.	0.8	27
45	Pharmacological Inhibition of Core Regulatory Circuitry Liquidâ€“liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. Advanced Science, 2021, 8, e2101895.	5.6	27
46	Machine learning uncovers cell identity regulator by histone code. Nature Communications, 2020, 11, 2696.	5.8	25
47	ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma. Aging, 2020, 12, 1808-1827.	1.4	25
48	The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer. Journal of Cancer, 2019, 10, 1398-1408.	1.2	24
49	BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. Oncogene, 2020, 39, 17-29.	2.6	22
50	RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma. International Journal of Oncology, 2019, 55, 645-656.	1.4	20
51	IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors. Molecular Therapy, 2020, 28, 1299-1313.	3.7	20
52	Androgen Receptor-Related Non-coding RNAs in Prostate Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 660853.	1.8	20
53	Impact of inflammation and immunotherapy in renal cell carcinoma (Review). Oncology Letters, 2020, 20, 1-1.	0.8	19
54	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12â€“8. European Urology, 2010, 58, e29-e30.	0.9	17

#	Article	IF	Citations
55	Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2. Molecular Cancer Therapeutics, 2020, 19, 2023-2033.	1.9	15
56	RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma. Experimental Cell Research, 2018, 372, 118-128.	1.2	14
57	Role of dutasteride in preâ€clinical ETS fusionâ€positive prostate cancer models. Prostate, 2012, 72, 1542-1549.	1.2	13
58	High SAA1 Expression Predicts Advanced Tumors in Renal Cancer. Frontiers in Oncology, 2021, 11, 649761.	1.3	13
59	Broad genic repression domains signify enhanced silencing of oncogenes. Nature Communications, 2020, 11, 5560.	5.8	10
60	LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation. Aging, 2020, 12, 17459-17479.	1.4	10
61	B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer. Asian Journal of Andrology, 2019, 21, 224.	0.8	8
62	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	13.7	6
63	High expression of TAZ serves as a novel prognostic biomarker and drives cancer progression in renal cancer. Experimental Cell Research, 2019, 376, 181-191.	1.2	6
64	TADsplimer reveals splits and mergers of topologically associating domains for epigenetic regulation of transcription. Genome Biology, 2020, 21, 84.	3.8	6
65	Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer. Oncogene, 2022, 41, 1610-1621.	2.6	6
66	The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma. Journal of Cancer, 2020, 11, 1712-1726.	1.2	5
67	Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. Oncology Reports, 2017, 37, 3651-3659.	1.2	4
68	MACMIC Reveals A Dual Role of CTCF in Epigenetic Regulation of Cell Identity Genes. Genomics, Proteomics and Bioinformatics, 2021, 19, 140-153.	3.0	4
69	Robot-assisted laparoscopic retroperitoneal leiomyosarcoma resection with inferior vena cava graft replacement: a case report. Translational Andrology and Urology, 2021, 10, 2133-2139.	0.6	4
70	CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials. Journal of Cancer Research and Therapeutics, 2020, 16, 990.	0.3	4
71	The screening of pivotal gene expression signatures and biomarkers in renal carcinoma. Journal of Cancer, 2019, 10, 6384-6394.	1.2	3
72	The Identification of Key Gene Expression Signature in Prostate Cancer. Critical Reviews in Eukaryotic Gene Expression, 2020, 30, 153-168.	0.4	3

#	Article	IF	Citations
73	LncGSEA: a versatile tool to infer lncRNA associated pathways from large-scale cancer transcriptome sequencing data. BMC Genomics, 2021, 22, 574.	1.2	2
74	Editorial: Response and Resistance in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 607298.	1.3	1